In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Molecular Inc.

www.abbottmolecular.com

Latest From Abbott Molecular Inc.

Roche Wins FDA Authorization On High-Volume Monkeypox Test

The test, which is the first for the condition to win an EUA using actual patient samples, provides results in about three and a half hours. 

Approvals FDA

FDA Clarifies Software Link In Abbott COVID-19 Lab Test Recall

The recall is related to the software’s mixing parameters, which may cause false positives if test samples contaminate each other.

Recalls Safety

Abbott COVID-19 Lab Test Recall Deemed High-Risk Class I

The recall is related to potential false positives that may occur if a genuine positive test sample overflows into an adjacent sample that would have otherwise tested negative.

Recalls Safety

US Regulatory Roundup, September 2021: Product Safety, Pediatric Devices, EUAs Revoked, And More

With news of high-risk medical device recalls and troubles with COVID-19 diagnostics, product safety was of paramount concern to Medtech Insight readers in September. Also topping the most-read list were articles focused on pediatric patients, the revocation of emergency use authorizations for products to treat and diagnose COVID-19, and more.

United States Regulation
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
UsernamePublicRestriction

Register